Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

310 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Regional Differences in Clinical Presentation and Prognosis of Patients With Post-Sustained Virologic Response Hepatocellular Carcinoma.
Toyoda H, Kanneganti M, Melendez-Torres J, Parikh ND, Jalal PK, Piñero F, Mendizabal M, Ridruejo E, Cheinquer H, Casadei-Gardini A, Weinmann A, Peck-Radosavljevic M, Dufour JF, Radu P, Shiha G, Soliman R, Sarin SK, Kumar M, Wang JH, Tangkijvanich P, Sukeepaisarnjaroen W, Atsukawa M, Uojima H, Nozaki A, Nakamuta M, Takaguchi K, Hiraoka A, Abe H, Matsuura K, Watanabe T, Shimada N, Tsuji K, Ishikawa T, Mikami S, Itobayashi E, Singal AG, Johnson PJ. Toyoda H, et al. Among authors: nakamuta m. Clin Gastroenterol Hepatol. 2024 Jan;22(1):72-80.e4. doi: 10.1016/j.cgh.2023.06.026. Epub 2023 Jul 11. Clin Gastroenterol Hepatol. 2024. PMID: 37442316
Efficacy of pegylated interferon alpha-2b and ribavirin treatment on the risk of hepatocellular carcinoma in patients with chronic hepatitis C: a prospective, multicenter study.
Ogawa E, Furusyo N, Kajiwara E, Takahashi K, Nomura H, Maruyama T, Tanabe Y, Satoh T, Nakamuta M, Kotoh K, Azuma K, Dohmen K, Shimoda S, Hayashi J; Kyushu University Liver Disease Study (KULDS) Group. Ogawa E, et al. Among authors: nakamuta m. J Hepatol. 2013 Mar;58(3):495-501. doi: 10.1016/j.jhep.2012.10.017. Epub 2012 Oct 23. J Hepatol. 2013. PMID: 23099187
Efficacy and safety of splenectomy in telaprevir-based triple therapy for chronic hepatitis C patients with thrombocytopenia and advanced fibrosis.
Ogawa E, Furusyo N, Nakamuta M, Kajiwara E, Nomura H, Dohmen K, Takahashi K, Satoh T, Azuma K, Kawano A, Tanabe Y, Kotoh K, Shimoda S, Akahoshi T, Maehara Y, Hayashi J; Kyushu University Liver Disease Study (KULDS) Group. Ogawa E, et al. Among authors: nakamuta m. J Gastroenterol Hepatol. 2014 Sep;29(9):1728-35. doi: 10.1111/jgh.12619. J Gastroenterol Hepatol. 2014. PMID: 24731162 Clinical Trial.
Pretreatment prediction of the outcome of response-guided peginterferon-α and ribavirin therapy for chronic hepatitis C.
Masaki N, Sugiyama M, Shimada N, Tanaka Y, Nakamuta M, Izumi N, Watanabe S, Tsubota A, Komatsu M, Masaki T, Enomoto N, Yoneda M, Murata K, Ito K, Koike K, Mizokami M. Masaki N, et al. Among authors: nakamuta m. J Gastroenterol Hepatol. 2014 Dec;29(12):1996-2005. doi: 10.1111/jgh.12646. J Gastroenterol Hepatol. 2014. PMID: 24910341 Free PMC article.
Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 2 hepatitis C virus infection.
Toyoda H, Chayama K, Suzuki F, Sato K, Atarashi T, Watanabe T, Atsukawa M, Naganuma A, Notsumata K, Osaki Y, Nakamuta M, Takaguchi K, Saito S, Kato K, Pugatch D, Burroughs M, Redman R, Alves K, Pilot-Matias TJ, Oberoi RK, Fu B, Kumada H. Toyoda H, et al. Among authors: nakamuta m. Hepatology. 2018 Feb;67(2):505-513. doi: 10.1002/hep.29510. Epub 2017 Nov 24. Hepatology. 2018. PMID: 28865152 Free PMC article. Clinical Trial.
Efficacy and safety of ombitasvir/paritaprevir/ritonavir and ribavirin for chronic hepatitis patients infected with genotype 2a in Japan.
Atsukawa M, Tsubota A, Toyoda H, Takaguchi K, Nakamuta M, Watanabe T, Tada T, Tsutsui A, Ikeda H, Abe H, Kato K, Uojima H, Ikegami T, Asano T, Kondo C, Koeda M, Okubo T, Arai T, Iwashita-Nakagawa A, Itokawa N, Kumada T, Iwakiri K. Atsukawa M, et al. Among authors: nakamuta m. Hepatol Res. 2019 Apr;49(4):369-376. doi: 10.1111/hepr.13292. Epub 2019 Jan 2. Hepatol Res. 2019. PMID: 30485638
Real-world virological efficacy and safety of daclatasvir/asunaprevir/beclabuvir in patients with chronic hepatitis C virus genotype 1 infection in Japan.
Takaguchi K, Toyoda H, Tsutsui A, Suzuki Y, Nakamuta M, Imamura M, Senoh T, Nagano T, Tada T, Tachi Y, Hiraoka A, Michitaka K, Shibata H, Joko K, Okubo H, Tsuji K, Takaki S, Watanabe T, Ogawa C, Chayama K, Kumada T, Kudo M, Kumada H. Takaguchi K, et al. Among authors: nakamuta m. J Gastroenterol. 2019 Aug;54(8):742-751. doi: 10.1007/s00535-019-01568-8. Epub 2019 Mar 8. J Gastroenterol. 2019. PMID: 30848363
The efficacy and safety of glecaprevir plus pibrentasvir in 141 patients with severe renal impairment: a prospective, multicenter study.
Atsukawa M, Tsubota A, Toyoda H, Takaguchi K, Nakamuta M, Watanabe T, Michitaka K, Ikegami T, Nozaki A, Uojima H, Fukunishi S, Genda T, Abe H, Hotta N, Tsuji K, Ogawa C, Tachi Y, Shima T, Shimada N, Kondo C, Akahane T, Aizawa Y, Tanaka Y, Kumada T, Iwakiri K. Atsukawa M, et al. Among authors: nakamuta m. Aliment Pharmacol Ther. 2019 May;49(9):1230-1241. doi: 10.1111/apt.15218. Epub 2019 Mar 14. Aliment Pharmacol Ther. 2019. PMID: 30873651 Clinical Trial.
310 results